Assertio Total Assets from 2010 to 2025

ASRT Stock

USD 0.72 0.01 1.41%

Assertio Therapeutics Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1997-09-30

Previous Quarter

276 M

Current Value

284.7 M

Quarterly Volatility

392 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Assertio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assertio Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.5 M, Total Revenue of 128.3 M or Gross Profit of 111.9 M, as well as many indicators such as Price To Sales Ratio of 0.63, Dividend Yield of 0.0 or PTB Ratio of 1.35. Assertio financial statements analysis is a perfect complement when working with Assertio Therapeutics Valuation or Volatility modules.

Check out the analysis of Assertio Therapeutics Correlation against competitors.

For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Latest Assertio Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Assertio Therapeutics over the last few years. Total assets refers to the total amount of Assertio Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Assertio Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Assertio Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assertio Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 284.73 M

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Assertio Total Assets Regression Statistics

	Arithmetic Mean	535,253,048
	Geometric Mean	289,388,404
	Coefficient Of Variation	75.67
	Mean Deviation	324,381,470
	Median	413,913,000
	Standard Deviation	405,009,943
	Sample Variance	164033.1T
	Range	1.4B
	R-Value	(0.05)
	Mean Square Error	175320.9T
	R-Squared	0
	Significance	0.86
	Slope	(4,201,824)
	Total Sum of Squares	2460495.8T

Assertio Total Assets History

	2025	335.7 M
	2024	284.7 M
	2023	286.4 M
	2022	413.9 M
	2021	326.5 M
	2020	303.3 M
	2019	527.2 M

Other Fundumenentals of Assertio Therapeutics

Intangibles To Total Assets

Assertio Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Investments	Intangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.75	0.74	0.34	0.6	0.79	0.98	0.59	0.85	0.41	0.57	0.96	0.87	0.61	-0.82	-0.24	0.93	-0.21	0.88	0.62	0.42	-0.33	-0.25
Total Stockholder Equity	0.75		0.22	0.39	0.57	0.52	0.6	0.85	0.71	0.56	0.51	0.63	0.57	0.51	-0.29	-0.3	0.51	-0.2	0.53	0.5	0.35	-0.13	-0.35
Net Debt	0.74	0.22		0.09	0.39	0.71	0.82	-0.08	0.59	0.08	0.21	0.86	0.65	0.4	-0.97	0.03	0.93	0.0	0.84	0.43	0.22	-0.23	-0.09
Retained Earnings	0.34	0.39	0.09		0.28	-0.11	0.3	0.39	0.48	0.39	0.67	0.36	0.55	-0.05	-0.12	0.53	0.24	-0.87	0.22	0.68	0.9	-0.85	-0.59
Accounts Payable	0.6	0.57	0.39	0.28		0.41	0.56	0.42	0.76	0.7	0.37	0.62	0.44	0.45	-0.42	-0.09	0.53	-0.2	0.64	0.77	0.22	-0.19	-0.08
Net Receivables	0.79	0.52	0.71	-0.11	0.41		0.8	0.33	0.67	0.24	0.33	0.79	0.58	0.81	-0.77	-0.43	0.81	0.12	0.78	0.34	-0.07	0.02	0.04
Total Liab	0.98	0.6	0.82	0.3	0.56	0.8		0.45	0.81	0.33	0.53	0.97	0.88	0.59	-0.91	-0.2	0.97	-0.19	0.91	0.59	0.41	-0.35	-0.2
Total Current Assets	0.59	0.85	-0.08	0.39	0.42	0.33	0.45		0.56	0.56	0.57	0.43	0.49	0.49	-0.05	-0.31	0.26	-0.3	0.27	0.38	0.38	-0.21	-0.18
Short Term Debt	0.85	0.71	0.59	0.48	0.76	0.67	0.81	0.56		0.71	0.61	0.88	0.76	0.56	-0.64	-0.03	0.77	-0.38	0.84	0.88	0.47	-0.41	-0.24
Short Term Investments	0.41	0.56	0.08	0.39	0.7	0.24	0.33	0.56	0.71		0.6	0.4	0.36	0.29	-0.1	0.12	0.23	-0.44	0.45	0.77	0.42	-0.2	-0.12
Common Stock	0.57	0.51	0.21	0.67	0.37	0.33	0.53	0.57	0.61	0.6		0.53	0.7	0.38	-0.32	0.17	0.42	-0.82	0.49	0.67	0.76	-0.63	-0.4
Long Term Debt	0.96	0.63	0.86	0.36	0.62	0.79	0.97	0.43	0.88	0.4	0.53		0.85	0.61	-0.89	-0.08	0.97	-0.24	0.93	0.67	0.44	-0.38	-0.22
Property Plant Equipment	0.87	0.57	0.65	0.55	0.44	0.58	0.88	0.49	0.76	0.36	0.7	0.85		0.38	-0.76	-0.1	0.83	-0.48	0.77	0.66	0.66	-0.56	-0.26
Current Deferred Revenue	0.61	0.51	0.4	-0.05	0.45	0.81	0.59	0.49	0.56	0.29	0.38	0.61	0.38		-0.48	-0.41	0.55	0.05	0.53	0.24	-0.11	-0.07	0.15
Net Tangible Assets	-0.82	-0.29	-0.97	-0.12	-0.42	-0.77	-0.91	-0.05	-0.64	-0.1	-0.32	-0.89	-0.76	-0.48		0.11	-0.97	0.05	-0.87	-0.46	-0.24	0.3	0.1
Long Term Investments	-0.24	-0.3	0.03	0.53	-0.09	-0.43	-0.2	-0.31	-0.03	0.12	0.17	-0.08	-0.1	-0.41	0.11		-0.13	-0.58	-0.1	0.28	0.53	-0.48	-0.27
Intangible Assets	0.93	0.51	0.93	0.24	0.53	0.81	0.97	0.26	0.77	0.23	0.42	0.97	0.83	0.55	-0.97	-0.13		-0.12	0.92	0.57	0.34	-0.32	-0.2
Capital Surpluse	-0.21	-0.2	0.0	-0.87	-0.2	0.12	-0.19	-0.3	-0.38	-0.44	-0.82	-0.24	-0.48	0.05	0.05	-0.58	-0.12		-0.19	-0.65	-0.89	0.77	0.49
Long Term Debt Total	0.88	0.53	0.84	0.22	0.64	0.78	0.91	0.27	0.84	0.45	0.49	0.93	0.77	0.53	-0.87	-0.1	0.92	-0.19		0.69	0.34	-0.2	-0.18
Short Long Term Debt	0.62	0.5	0.43	0.68	0.77	0.34	0.59	0.38	0.88	0.77	0.67	0.67	0.66	0.24	-0.46	0.28	0.57	-0.65	0.69		0.66	-0.56	-0.34
Net Invested Capital	0.42	0.35	0.22	0.9	0.22	-0.07	0.41	0.38	0.47	0.42	0.76	0.44	0.66	-0.11	-0.24	0.53	0.34	-0.89	0.34	0.66		-0.76	-0.56
Net Working Capital	-0.33	-0.13	-0.23	-0.85	-0.19	0.02	-0.35	-0.21	-0.41	-0.2	-0.63	-0.38	-0.56	-0.07	0.3	-0.48	-0.32	0.77	-0.2	-0.56	-0.76		0.43
Capital Stock	-0.25	-0.35	-0.09	-0.59	-0.08	0.04	-0.2	-0.18	-0.24	-0.12	-0.4	-0.22	-0.26	0.15	0.1	-0.27	-0.2	0.49	-0.18	-0.34	-0.56	0.43

Click cells to compare fundamentals

About Assertio Therapeutics Financial Statements

Assertio Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Assertio Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Assertio Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Assertio Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	284.7 M	335.7 M
Intangibles To Total Assets	0.28	0.41

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC